Will Obamacare Harm These Biotech Stocks?

The Affordable Care Act, also known as Obamacare as it is president Obama's signature health care law, is broadly acknowledged as a far-reaching law that affects many parts of the U.S. health care system. Obamacare's provisions are recognized to affect the competitive landscape for insurers, hospitals, and pharmaceutical benefit managers. But did you know that Obamacare also directly affects biotech stocks?

In its most recent 10-K, Celgene  (NASDAQ: CELG  ) acknowledged this reality by stating that "The Affordable Care Act will affect our profitability." Unfortunately, how much and in what way is difficult to predict, as the 10-K continues,

"We expect that the rebates, discounts, taxes and other costs resulting from the Affordable Care Act will have a significant effect on our profitability in the future. In addition, potential reductions of the per capita rate of growth in Medicare spending under the Affordable Care Act, could potentially limit access to certain treatments or mandate price controls for our products. Similarly, the promulgation of new regulations concerning rebates, discounts, taxes and other costs, or the interpretation and enforcement of new or existing regulations by government agencies could affect our profitability in ways that are difficult to predict."

In this video, Motley Fool analysts David Williamson and Michael Douglass discuss which biotechs investors should watch and which drugs may be most affected by the law.

What other stocks does Obamacare affect?
Obamacare seems complex, but it doesn't have to be. In only minutes, you can learn the critical facts you need to know in a special free report called "Everything You Need to Know About Obamacare." This FREE guide contains the key information and money-making advice that every American must know. Please click here to access your free copy.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2877170, ~/Articles/ArticleHandler.aspx, 9/5/2015 8:17:45 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Michael Douglass

As the Motley Fool's Health Care Editor/Analyst, I focus on all things health care -- although my greatest interest is in the megatrends reshaping the American health care system, including the Affordable Care Act, Accountable Care Organizations, a shifting regulatory landscape, and the new drug discoveries fundamentally changing disease management and treatment.

Today's Market

updated 11 hours ago Sponsored by:
DOW 16,102.38 -272.38 -1.66%
S&P 500 1,921.22 -29.91 -1.53%
NASD 4,683.92 -49.58 -1.05%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/4/2015 4:00 PM
ABBV $59.77 Down -1.81 -2.94%
AbbVie Inc. CAPS Rating: ****
GILD $102.06 Up +0.15 +0.15%
Gilead Sciences CAPS Rating: *****
CELG $117.39 Down -0.26 -0.22%
Celgene CAPS Rating: *****